S&P UNITED KINGDOM (PDS) Share Price

Index

Market Closed - USA 09:59:21 31/05/2024 pm IST			5-day change	1st Jan Change
1,678 ^PTS	+0.59%		-0.69%	+7.16%

31/05	London Stocks Rally Amid US, Eurozone Inflation Data	MT
31/05	FTSE 100 rounds off decent May with gain	AN

Duration

Period

Style

London Stocks Rally Amid US, Eurozone Inflation Data	31/05	MT
FTSE 100 rounds off decent May with gain	31/05	AN
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	31/05	MT
FTSE 100 outperforms European counterparts	31/05	AN
UK-based CFO leaves Flutter as US becomes primary listing	31/05	AN
FTSE 100 up as markets wait for US PCE reading	31/05	AN
London stocks little changed as US, Euro inflation data loom	31/05	RE
FTSE 100 called up; UK house prices show resilience	31/05	AN
Investors nervously eye key US PCE reading	31/05	AN
AB Foods majority investor to sell GBP273 million worth of shares	30/05	AN
Auto Trader Group Drives UK's FTSE 100 Index Recovery	30/05	MT
Lists in green; focus on tomorrow's inflation	30/05	AN
Auto Trader shines thanks to annual results	30/05	AN
UK's Auto Trader shares hit record high as annual profit jumps	30/05	RE
FTSE 100 at near one-month low ahead of US inflation data; Anglo drops	30/05	RE

Standard Chartered Buys Back Shares STAN	07:07am	MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results AZN	03/06	RE
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial AZN	03/06	BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial AZN	02/06	PU
Astra's Enhertu delays breast cancer in patients with low HER2 levels AZN	02/06	RE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo AZN	02/06	BU
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified AZN	02/06	RE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy AZN	02/06	BU
Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal AZN	01/06	MT
BlackRock Throgmorton Trust Plc - Transaction in Own Shares THRG	31/05	PR

No results for this search

Borsa: l'Europa chiude a due velocità	31/05
Listini in verde; focus su inflazione di domani	30/05
Actualización de las fuertes variaciones del día: Dr Martens, LDC, OVH Groupe, Neoen y muchos otros.	30/05
Borse in rosso; scatto di DiaSorin sul Mib	29/05
Actualización de las fuertes variaciones del día: Ocado, Waga Energy, Volkswagen y otros	29/05